Compare DHC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHC | OGN |
|---|---|---|
| Founded | 1998 | 1923 |
| Country | United States | United States |
| Employees | 585 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | DHC | OGN |
|---|---|---|
| Price | $7.37 | $9.69 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $7.25 | ★ $11.75 |
| AVG Volume (30 Days) | 1.4M | ★ 6.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | 0.56% | ★ 0.86% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $3.13 | $0.45 |
| Revenue Next Year | $7.00 | $1.67 |
| P/E Ratio | ★ N/A | $12.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $5.69 |
| 52 Week High | $7.66 | $13.25 |
| Indicator | DHC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 76.35 |
| Support Level | $6.46 | $8.63 |
| Resistance Level | $7.64 | $10.10 |
| Average True Range (ATR) | 0.30 | 0.58 |
| MACD | 0.03 | 0.42 |
| Stochastic Oscillator | 85.64 | 96.66 |
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.